Safety and efficacy of combined use of low molecular weight heparin (enoxaparin, lovenox) and glycoprotein IIb/IIIa receptor antago- nist (eptifibatide,integrelin)during nonemergent coronary and peripheral vascular intervention. Am J Ther 2002; 9: 488-491...
In a specific embodiment, the low molecular weight heparin is administered first, followed by administration of the ht-PA variant as a weight-adjusted single bolus. [0017] The low molecular weight heparin, e.g. enoxaparin, is typically administered as an intravenous bolus followed by ...
Information on thrombocytopenia (low blood platelet count) causes such as medication (for example, heparin), viral infections, alcohol abuse, cancers, and rheumatologic conditions. Symptoms, diagnosis, and treatment options are provided.
Increased dose requirements for Enoxiparin (Lovenox??) Low Molecular Weight Heparin (LMWH) in neonates, children, and adolescentsAn abstract is unavailable.doi:10.1097/00043426-200007000-00027Douglas GrahamMarilyn J. Manco-JohnsonTaru HaysJames Murphy...
The patent protection of low-molecular-weight heparins (LMWHs) expired, so the definition of criteria for the biological similarity between LMWH copies and the original product is a real need.The present in vitro study compared copies and branded enoxaparin using the specific anti-Xa activity and...